Goldman Sachs Maintains Buy on Guardant Health, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on Guardant Health (NASDAQ:GH) and raises the price target from $28 to $32.
July 17, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on Guardant Health and raises the price target from $28 to $32.
The Buy rating and increased price target from a reputable analyst at Goldman Sachs is likely to positively influence investor sentiment and drive short-term price appreciation for Guardant Health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100